Table 4 Demographic and Clinical Characteristics of Belatacept and Control patients
Cohort characteristics | Belatacept (N = 30) | CNI (N = 56) | P value |
|---|---|---|---|
Age (y) | 53.5 ± 26 | 52.0 ± 21 | 0.700 |
Donor age (y) | 48.0 ± 23 | 46.0 ± 23 | 0.907 |
Gender (m/f) | 20/10 | 19/37 | 0.956 |
Post-transplant diabetes | 3/30 | 5/56 | 0.871 |
BMI | 25.3 ± 4.1 | 22.9 ± 8.3 | 0.213 |
Systolic BP (mmHg) | 134 ± 17 | 130 ± 51 | 0.076 |
Diastolic BP (mmHg) | 84 ± 10 | 80 ± 13 | 0.054 |
Time after transplantation (m) | 127.5 ± 91.3 | 113.0 ± 102.5 | 0.500 |
eGFR (mL/min) | 22.5 ± 12 | 24.5 ± 14 | 0.583 |
eGFR < 25 mL/min | 17/30 | 28/56 | 0.667 |
Proteinuria (mg/g creatinine) | 840 ± 1166 | 280.5 ± 1270 | 0.157 |
Living donor transplants | 8/30 | 8/56 | |
Pancreas/kidney | 2/30 | 6/56 | |
Immunosuppression | |||
 Tacrolimus | 22/30 | 42/56 | 0.867 |
 Cyclosporine A | 8/30 | 14/56 | 0.867 |
 Mycophenolic acid | 27/30 | 54/56 | 0.227 |
 Azathioprin | 2/30 | 0/56 | 0.052 |
 Steroid | 24/30 | 45/56 | 0.969 |
DSA | 14/30 | 19/56 | 0.336 |
h/o any rejection | 15/30 | 20/56 | 0.201 |
aTCMR | 3/30 | 7/56 | 0.732 |
aABMR | 6/30 | 12/56 | 0.990 |
Histology before switch (m) | 5 ± 11.3 | 9.5 ± 26.5 | 0.236 |
Biopsy scores | |||
 glomerular scarring (%) | 30.5 ± 33 | 28.5 ± 45 | 0.942 |
 cg | 0.0 ± 3.0 | 0.0 ± 1.4 | 0.202 |
 ct | 1.0 ± 1.0 | 1.0 ± 1.0 | 1.000 |
 ci | 1.0 ± 1.0 | 1.0 ± 1.0 | 0.705 |
 cv | 2.0 ± 2.0 | 1.0 ± 1.0 | 0.368 |
 mm | 1.0 ± 2.0 | 1.0 ± 2.0 | 0.845 |
 ah | 3.0 ± 0.0 | 2.75 ±1.0 | 0.003 |
 g | 0.0 ± 1.0 | 0.0 ± 0.0 | 0.307 |
 t | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.865 |
 i | 0.0 ± 0.0 | 0.0 ± 1.0 | 0.243 |
 v | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.129 |
 ptc | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.956 |
 diffuse ptc (y/n) | 0/30 | 3/56 | 0.333 |
 C4d | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.000 |
 MVI sum score | 0.0 ± 1.3 | 0.0 ± 1.0 | 0.448 |
 MVI sum score ≧2 | 7/30 | 8/56 | 0.295 |